This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Ophthalmic Disease Animal Model Development Service
Introduction
Facing hurdles in ophthalmic preclinical development, complicated by the need for relevant disease models? BioVenic offers a comprehensive solution. BioVenic's ophthalmic disease animal model development services simplify your R&D pipeline by providing diverse animal model construction, robust validation, and integrated downstream assay execution. We help you establish high-quality, non-GLP models to accelerate the efficacy and safety assessment of your novel compounds and devices.
BioVenic Ophthalmic Disease Animal Model Development Services
Ophthalmic Disease Animal Model Development
BioVenic provides expert construction of a wide spectrum of ophthalmic disease animal models, covering the anterior and posterior segments of the eye. Beyond common models, we specialize in customized model generation to meet your specific research goals. This customized approach, utilizing a range of established species from mice to non-human primates, ensures maximal translational relevance for your studies.
Ophthalmic Disease Animal Model Validation and Characterization
The quality of your data depends entirely on the fidelity of the model. BioVenic performs thorough, non-GLP validation checks to confirm the disease was successfully induced and remains stable throughout the study. This validation typically includes:
- Physical and Functional Checks: Precisely measuring Intraocular Pressure (IOP) with tonometry, assessing tear film health (Schirmer's, tear break-up time), and testing visual function using specialized behavioral or electrophysiological assays (ERG).
- Advanced Ocular Imaging: Using state-of-the-art techniques like Optical Coherence Tomography (OCT) to visualize and quantify damage to the retina (e.g., retinal thinning, measuring CNV lesion size) and Fluorescein Angiography (FA) to detect and quantify vascular leakage.
- Pathology Confirmation: Standard histological analysis (H&E) and targeted immunohistochemistry on eye cross-sections to definitively confirm pathology, such as neuronal loss in the retina or fibrosis.
Ophthalmic Biospecimen Collection and Bioanalysis
BioVenic offers targeted, precise collection of critical ophthalmic biospecimens for downstream analysis. Our expertise ensures high-quality sample preparation from various ocular structures, including:
- Ocular Tissues: Retina, choroid, RPE, cornea, lens, optic nerve, vitreous humor, and aqueous humor.
- Systemic Samples: Blood, plasma, serum, and urine.
- Cell isolates: Primary retinal cells, RPEs, fibroblasts, primary corneal epithelial cells, etc.
These samples can be used for pharmacokinetics (PK), target engagement, biomarker analysis, and gene expression profiling.
Integrated Downstream Experimental Studies on Ophthalmic Disease Animal Models
Leveraging our validated models, BioVenic executes a suite of non-GLP preclinical studies. Explore BioVenic's investigative modalities:
- Animal Behavioral Analysis
- Animal Histopathology Service
- Preclinical Animal Pharmacodynamics (PD) Study
- Preclinical Animal Pharmacokinetics (PK) Study
- Animal Cell Biology Service
- Animal lmaging Service
BioVenic's animal ophthalmic disease model related services include:
- Genome-edited Animal Model Development
- Chemically-induced Animal Model Development
- Surgically-induced Animal Model Development
Development Workflow for an Ophthalmic Disease Animal Model
BioVenic's streamlined process ensures efficient execution of your preclinical research:
Ophthalmic Disease Animal Models and Application Fields
Table. 1 Common Ophthalmic Disease Animal Models and Application Fields
| Ophthalmic Disease Model | Induction/Modeling Method | Animal Species | Key Applications |
|---|---|---|---|
| Glaucoma |
Acute Ocular Hypertension (OHT): Anterior chamber injection of viscoelastic agents, or hypertonic saline injection into episcleral veins. Chronic OHT: Anterior chamber injection of magnetic microbeads or microspheres (often followed by magnetic direction), laser photocoagulation of the trabecular meshwork/scleral veins, or TGF-beta II/silicone oil injection. Normal IOP Glaucoma: NMDA-induced retinal ganglion cell (RGC) damage, or optic nerve crush/clamping. |
Rats, Mice, Rabbits, NHP | Studying intraocular pressure (IOP) regulation, RGC protection, optic nerve damage and neurodegeneration, and evaluating anti-glaucoma drugs/gene therapies. |
| Dry Eye Disease (DED) |
Evaporative/Inflammatory: Exposure to desiccating stress (low humidity/airflow), topical application of Benzalkonium Chloride (BAC), or Scopolamine/Atropine injection/administration (to inhibit tear secretion). Aqueous-Deficient: Surgical removal of the lacrimal gland. Sjögren's Syndrome: Spontaneous/induced autoimmune models. |
Mice, Rats, Rabbits, Guinea Pigs | Evaluating tear film stability, ocular surface inflammation, testing artificial tears, anti-inflammatory agents, and secretagogues. |
| Wet Age-related Macular Degeneration (wAMD)/ Choroidal Neovascularization (CNV) |
Laser-induced CNV: Focal laser photocoagulation to rupture Bruch's membrane, inducing a neovascular response from the choroid. Genetic Models: Humanized VEGF (VEGFA/ANG2) overexpression transgenic mice or specific knockout/knock-in mouse lines. |
Mice, Rabbits, NHP | Testing anti-VEGF therapies, investigating the pathogenesis of neovascularization, and evaluating new agents for retinal and subretinal fibrosis. |
| Dry Age-related Macular Degeneration (dAMD)/ Retinal Degeneration |
Drug Induction: Intravenous or subretinal injection of Sodium Iodate or MNU to target the RPE and photoreceptors. Light Damage: Exposure to intense blue or white light. Genetic Models: Complement-activated (C3/C5/CFB humanized) mice, or models with RPE-specific oxidative stress. |
Mice, Rats, Rabbits, NHP (spontaneous) | Studying RPE cell toxicity, oxidative stress, complement system involvement, and testing neuroprotective/cell replacement therapies. |
| Cataract |
Drug/Chemical Induction: Injection of Sodium Selenite or high glucose/galactose feeding (for diabetic/galactosemic cataract). Age-related: Spontaneous models in NHP. |
Rats, Mice, Rabbits, Zebrafish, NHP | Research on cataractogenesis mechanisms, screening anti-cataract agents, and modeling surgical/post-surgical complications. |
| Myopia (Nearsightedness) |
Form-Deprivation Myopia (FDM): Suturing the eyelids or applying diffusers over the eye. Lens-Induced Myopia (LIM): Placing negative defocus lenses in front of the eye. |
Guinea Pigs, Tree Shrews, Mice, Chicks, Monkeys | Studying the molecular pathways of eye growth, evaluating therapeutic spectacles, and testing pharmacological interventions to slow down axial elongation. |
| Retinal Neovascularization (RNV)/ Diabetic Retinopathy (DR) |
Oxygen-Induced Retinopathy (OIR): Exposing newborn pups to hyperoxia (high oxygen) followed by normoxia (room air), causing pathological neovascularization. Diabetic Models: Streptozotocin (STZ) injection to induce hyperglycemia (DR), or VEGF injection. |
Mice, Rats, Rabbits | Investigating abnormal vascular growth (proliferative DR, ROP), studying blood-retinal barrier breakdown, and testing anti-angiogenic drugs. |
| Optic Nerve Injury/Neuropathy |
Optic nerve crush or transection (clamping/cutting) near the globe. Ischemia/Reperfusion: Acute high IOP induction followed by release (for RGC ischemia). |
Rats, Mice | Research on axonal regeneration, RGC survival, and testing neuroprotective strategies for optic neuropathies. |
Advantages of BioVenic Ophthalmic Disease Animal Model Development Service
Versatile Model Construction
BioVenic offers a multi-platform approach, skillfully integrating genetic editing, chemical induction, surgical techniques, and optical methods to select or construct the most appropriate model. We meticulously choose the right animal species (from mice to NHP) and induction protocol to meet the specific requirements of your research question.
Tailored Project Customization
Based on your foundational research and specific experimental goals, BioVenic team delivers fully customized protocols. This includes selecting the optimal animal model, developing precise dosing schedules, and designing a detection plan that ensures scientifically sound conclusions.
Robust Validation and Analytical Capabilities
Beyond model building, BioVenic's strength lies in our powerful detection platform. We utilize cutting-edge imaging (OCT, FA) and have a comprehensive bioanalysis capability for animal biochemical, molecular, and histopathological readouts. This ensures rigorous model validation and provides reliable data for your compounds' effects.
End-to-End Integrated Services
BioVenic eliminates the logistical and scientific challenges of working with multiple vendors. Our offering is a single-source solution, encompassing model construction, validation, in-life animal studies, and sample analysis. This integrated approach ensures seamless project flow and scientific consistency, allowing you to focus on your research outcomes.
Case Study: Standardized Rabbit Dry Eye Model & Ocular Efficacy
BioVenic's platform offers a highly reproducible animal model of dry eye via the standardized topical administration of benzalkonium chloride (BAC), inducing consistent chronic ocular surface damage. To ensure rigorous modeling validation, we provide comprehensive longitudinal monitoring, such as tear film kinetics, alongside precise quantification of corneal epithelial integrity through fluorescein staining. Our advanced diagnostic suite further includes conjunctival impression cytology to characterize goblet cell depletion and ocular surface remodeling. By delivering stable, quantifiable disease parameters, we help you accelerate the evaluation of treatments aimed at restoring the ocular microenvironment.
Fig. 1 Representative pictures of HE staining of the corneas.1
FAQs
Q: Are your studies GLP compliant?
A: We specialize in providing high-quality, reproducible non-GLP preclinical studies. BioVenic's rigorous scientific standards and documentation are designed to support your early efficacy and mechanism of action studies prior to formal regulatory submission.
Q: How do you ensure the model accurately reflects the human disease?
A: We employ both gold-standard and custom models. We use multiple validation methods to verify that the animal model exhibits the key pathological hallmarks (e.g., RGC loss, neovascularization, tear film dysfunction) relevant to the human condition.
Q: What species can you provide for our preclinical studies?
A: Our BioVenic Team routinely works with a wide range of species, including Mice (various strains), Rats, Rabbits, Guinea Pigs, Pigs, and Non-Human Primates (NHP), ensuring we select the most anatomically and physiologically relevant model for your specific eye disease.
Contact Us
Ophthalmic disease animal models are the critical link connecting foundational science to clinical potential. By providing highly relevant, rigorously validated models and a full suite of integrated downstream services-from complex gene-edited model development to comprehensive bioanalysis-BioVenic accelerates your preclinical research and de-risk your program. Contact us today to discuss your specific model needs and receive a tailored quotation to advance your ophthalmic research with confidence and precision.
Reference
- Li, Chaoyang et al. "Research on the stability of a rabbit dry eye model induced by topical application of the preservative benzalkonium chloride." PloS one vol. 7,3 (2012): e33688. https://doi.org/10.1371/journal.pone.0033688. Distributed under Open Access license CC BY 4.0. Without modification.